Eliyahou Et Al Harari Buys 13,850 Shares of CapsoVision (NASDAQ:CV) Stock

CapsoVision, Inc. (NASDAQ:CV) major shareholder Eliyahou Et Al Harari purchased 13,850 shares of the business’s stock in a transaction on Friday, June 26th. The shares were bought at an average cost of $7.35 per share, for a total transaction of $101,797.50. Following the purchase, the insider owned 3,200,751 shares of the company’s stock, valued at $23,525,519.85. This trade represents a 0.43% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

CapsoVision Stock Down 5.9%

Shares of NASDAQ CV opened at $5.77 on Friday. The stock has a market capitalization of $288.27 million and a PE ratio of -2.47. The firm has a fifty day moving average of $6.87 and a 200-day moving average of $6.71. CapsoVision, Inc. has a 52-week low of $3.43 and a 52-week high of $15.37.

CapsoVision (NASDAQ:CV) last issued its earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share for the quarter. The company had revenue of $2.79 million during the quarter.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of CapsoVision in a research report on Monday, June 29th. Benchmark decreased their price objective on shares of CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating for the company in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.50.

Institutional Trading of CapsoVision

Large investors have recently bought and sold shares of the company. Deutsche Bank AG purchased a new stake in shares of CapsoVision during the fourth quarter valued at approximately $47,000. Wells Fargo & Company MN grew its holdings in CapsoVision by 66.4% during the 4th quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after purchasing an additional 2,508 shares in the last quarter. Virtu Financial LLC purchased a new stake in CapsoVision during the 4th quarter worth $128,000. Millennium Management LLC acquired a new position in CapsoVision in the 4th quarter worth $163,000. Finally, Bank of America Corp DE lifted its holdings in CapsoVision by 528.9% in the 1st quarter. Bank of America Corp DE now owns 22,238 shares of the company’s stock worth $162,000 after buying an additional 18,702 shares in the last quarter.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.